Skip to search formSkip to main contentSkip to account menu

Erbitux

National Institutes of Health

Related topics

Related topics

2 relations
50 ML cetuximab 2 MG/ML Injection [Erbitux]

Broader (1)

cetuximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
СОВРЕМЕННЫЕ ПОДХОДЫ К ЛУЧЕВОМУ ЛЕЧЕНИЮ ОПУХОЛЕЙ ПОЛОСТИ РТА
Growth of frequency of squamous cell cancer of oropharynx and dominance of locally-spread forms of a tumor at 60 % with the early… 
2014
2014
Changes of TCR repertoire diversity in colorectal cancer after Erbitux (cetuximab) in combination with chemotherapy.
We have previous found a positive correlation between post-therapy TCR repertoire normalization and remission of colorectal… 
2013
2013
Imaging specificity of MR-optical imaging agents following the masking of surface charge by poly(ethylene glycol).
2013
2013
A Postmarketing Surveillance Study on Erbitux (Cetuximab) in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-Containing Treatment
Objective This postmarketing surveillance study evaluated the safety and efficacy of cetuximab therapy in patients with epidermal… 
2013
2013
CORECT - Erbitux: stav registru k datu 7. 10. 2013
Registr CORECT je neintervencni poregistreacni databaze zaměřena na sběr epidemiologických a klinických dat pacientů s diagnozou… 
2012
2012
Efficacy of vemurafenib (V), a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer…
494 Background: B-Raf mutations, particularly at V600 occur in 10% of CRCs resulting in constitutive activation of the MAPK… 
2011
2011
Efficacy of vemurafenib (V), a selective V600Eb-raf inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer…
e13554 Background: B-Raf mutations, particularly at V600E occur in 8%-30% of CRCs resulting in constitutive activation of the MEK… 
2009
2009
Developing tools for stratified medicine
Establishing a common language for the stakeholders in stratified medicine — including drug developers, diagnostic companies… 
2008
2008
Aktuální klinické informace - Erbitux (cetuximab) - Nádoryhlavy a krku
Autoři popisuji soucasne možnosti lecby karcinomů hlavy a krku a zaměřuji se hlavně na cilenou lecbou 
2003
2003
Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)